HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Prima

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Virology

• Publication date

  2017-02-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.02182-16PMID 28179536PMCID PMC5391471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Determinants of HIV-1 broadly neutralizing antibody induction

  2016cited by this paper
• Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques

  2016cited by this paper
• Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

  2016cited by this paper
• Interleukin-1- and Type I Interferon-Dependent Enhanced Immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef Vaccine Vector with Dual Deletions of Type I and Type II Interferon-Binding Proteins

  2015cited by this paper
• Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection

  2015cited by this paper
• Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates

  2015cited by this paper
• Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost

  2015cited by this paper
• Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1.

  2015cited by this paper
• Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys

  2015cited by this paper
• Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines

  2014cited by this paper
• Enhancing poxvirus vectors vaccine immunogenicity

  2014cited by this paper
• Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection

  2014cited by this paper
• HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

  2014cited by this paper
• Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells.

  2014cited by this paper
• Deletion of the Vaccinia Virus N2L Gene Encoding an Inhibitor of IRF3 Improves the Immunogenicity of Modified Vaccinia Virus Ankara Expressing HIV-1 Antigens

  2014cited by this paper
• Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles

  2014cited by this paper
• Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination

  2014cited by this paper
• CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants

  2014cited by this paper
• Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.

  2013cited by this paper
• Intranasal Vaccination

  2013cited by this paper
• High Antibody-Dependent Cellular Cytotoxicity Responses Are Correlated with Strong CD8 T Cell Viral Suppressive Activity but Not with B57 Status in HIV-1 Elite Controllers

  2013cited by this paper
• Immunological and Virological Mechanisms of Vaccine-Mediated Protection Against SIV and HIV

  2013cited by this paper
• Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates

  2013cited by this paper
• Detection of HIV-1 Neutralizing Antibodies in a Human CD4+/CXCR4+/CCR5+ T-Lymphoblastoid Cell Assay System

  2013cited by this paper
• Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

  2013cited by this paper
• Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

  2013cited by this paper
• Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways

  2013cited by this paper
• Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C

  2013cited by this paper
• Novel directions in HIV-1 vaccines revealed from clinical trials.

  2013cited by this paper
• Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family

  2012cited by this paper
• OMIP‐005: Quality and phenotype of antigen‐responsive rhesus macaque T cells

  2012cited by this paper
• Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

  2012cited by this paper
• NYVAC immunization induces polyfunctional HIV‐specific T‐cell responses in chronically‐infected, ART‐treated HIV patients

  2012cited by this paper
• Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.

  2012cited by this paper
• Improving the MVA Vaccine Potential by Deleting the Viral Gene Coding for the IL-18 Binding Protein

  2012cited by this paper
• Removal of Vaccinia Virus Genes That Block Interferon Type I and II Pathways Improves Adaptive and Memory Responses of the HIV/AIDS Vaccine Candidate NYVAC-C in Mice

  2012cited by this paper
• Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens

  2012cited by this paper
• Poxvirus vectors as HIV/AIDS vaccines in humans

  2012cited by this paper
• DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell Responses in Intestinal Mucosa

  2011cited by this paper
• Improved NYVAC-Based Vaccine Vectors

  2011cited by this paper
• High‐throughput quantitative analysis of HIV‐1 and SIV‐specific ADCC‐mediating antibody responses

  2011cited by this paper
• A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses

  2011cited by this paper
• Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors

  2011cited by this paper
• Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens

  2010cited by this paper
• Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions

  2010cited by this paper
• Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.

  2010cited by this paper
• Poxvirus vector-based HIV vaccines

  2010cited by this paper
• Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.

  2009cited by this paper
• Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

  2009cited by this paper
• Preclinical Evaluation of the Immunogenicity of C-Type HIV-1-Based DNA and NYVAC Vaccines in the Balb/C Mouse Model

  2009cited by this paper
• A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal Vaccination

  2009cited by this paper
• Measuring HIV neutralization in a luciferase reporter gene assay.

  2009cited by this paper
• Comparison of Human and Rhesus Macaque T-Cell Responses Elicited by Boosting with NYVAC Encoding Human Immunodeficiency Virus Type 1 Clade C Immunogens

  2009cited by this paper
• EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

  2008cited by this paper
• EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.

  2008cited by this paper
• Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination.

  2008cited by this paper
• Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia

  2008cited by this paper
• Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes.

  2008cited by this paper
• An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

  2008cited by this paper
• Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates.

  2008cited by this paper
• Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic

  2008cited by this paper
• Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

  2007cited by this paper
• Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.

  2007cited by this paper
• Compact, synthetic, vaccinia virus early/late promoter for protein expression.

  1997cited by this paper
• Vaccinia Virus B18R Gene Encodes a Type I Interferon-binding Protein That Blocks Interferon α Transmembrane Signaling (*)

  1995cited by this paper
• Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity.

  1995cited by this paper
• Differential CD4 (cid:1) versus CD8 (cid:1) T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates (cid:1) †

  year unknowncited by this paper

• Intranasal immunization of recombinant vaccinia virus bearing FeLV SU elicits systemic and mucosal immunity.

  2025cites this paper
• Progress and prospects on vaccine development against monkeypox infection

  2023cites this paper
• Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases

  2023cites this paper
• Glycosylated protein 4-deficient PRRSV in complementing cell line shows low virus titer.

  2023cites this paper
• Rendezvous with Vaccinia Virus in the Post-smallpox Era: R&D Advances

  2023cites this paper
• Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study

  2022cites this paper
• Genomic accordions may hold the key to Monkeypox Clade IIb's increased transmissibility.

  2022cites this paper
• Intranasal Immunization with a Vaccinia Virus Vaccine Vector Expressing Pre-Fusion Stabilized SARS-CoV-2 Spike Fully Protected Mice against Lethal Challenge with the Heavily Mutated Mouse-Adapted SARS2-N501YMA30 Strain of SARS-CoV-2

  2022cites this paper
• Fengreqing Oral Liquid Exerts Anti-Inflammatory Effects by Promoting Apoptosis and Inhibiting PI3K/AKT and NF-κB Signaling Pathways

  2022cites this paper
• Intranasal immunization with a vaccinia virus vaccine vector expressing pre-fusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501YMA30 strain of SARS-CoV-2

  2021cites this paper
• Administration with Vaccinia Virus Encoding Canine Parvovirus 2 vp2 Elicits Systemic Immune Responses in Mice and Dogs

  2020cites this paper
• HIV Env-Specific IgG Antibodies Induced by Vaccination of Neonatal Rhesus Macaques Persist and Can Be Augmented by a Late Booster Immunization in Infancy

  2020cites this paper
• Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV

  2019cites this paper
• A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses

  2019cites this paper
• Intranasal immunization with recombinant Vaccinia virus Tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice.

  2019cites this paper
• Modified Vaccinia Virus Ankara Can Induce Optimal CD8+ T Cell Responses to Directly Primed Antigens Depending on Vaccine Design

  2019cites this paper
• CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention

  2019cites this paper
• Improved immune response against HIV‐1 Env antigen by enhancing EEV production via a K151E mutation in the A34R gene of replication‐competent vaccinia virus Tiantan

  2018cites this paper
• Apoptosis and apoptotic body: disease message and therapeutic target potentials

  2018cites this paper
• Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC

  2018cites this paper
• Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost

  2018cites this paper
• Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines

  2018cites this paper
• Passive and active antibody studies in primates to inform HIV vaccines

  2018cites this paper
• AIDS Clinical Research in Spain—Large HIV Population, Geniality of Doctors, and Missing Opportunities

  2018cites this paper
• Challenges and Achievements in Prevention and Treatment of Smallpox

  2018cites this paper
• Novel Concepts for HIV Vaccine Vector Design

  2017cites this paper
• Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology

  2017cites this paper